2022
The first two participants of the SHIELD trial (PENTA-22) were screened by Dr. Renate Strehlau and her team at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa in June 2022. SHIELD is the first paediatric trial on Fostemsavir, targeting children living with HIV that have developed resistance to two or more antiretroviral drug classes.
SHIELD aims to evaluate the safety of fostemsavir when taken with optimized background antiretroviral therapy.